Conmed (CNMD) Tops Q4 EPS by 4c, Beats on Revenues; Offers FY18 EPS Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
CONMED (CNMD) PT Raised to $54 at Piper Jaffray
February 1, 2018 6:41 AM ESTPiper Jaffray raised its price target on CONMED (NASDAQ: CNMD) to $54.00 (from $46.00) while maintaining a Neutral rating.
... MoreCONMED (CNMD) PT Raised to $71 at Needham & Company
February 1, 2018 6:22 AM ESTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $71.00 (from $58.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 4Q17 revenue and EPS beat consensus and management guided to above-consensus 2018 revenue and EPS. Its revenue growth improved to... More
